NATERA Plant-Based, Meat Alternative Entrees Now Available in Denny's Restaurants Across Canada

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) is pleased to announce that Denny's restaurants in Canada has officially launched (2) NATERA plant-based, meat-alternative entrees on their menus in all its Denny's restaurants and Bar One locations across Canada

As reported on August 26, 2021, Denny's is offering NATERA Seasoned Chick-Un Tenders and Chick-Un Nuggets at seventy-one (71) Denny's across Canada and thirteen (13) Bar One locations in BC and Alberta. Bar One is a restaurant under the Denny's Canada brand. The Seasoned Chick-Un Tenders and the Chick-Un Nuggets are served using Denny's signature seasonings and sauces, making them unique for their much-valued customers across Canada.

Naturally Splendid is pleased to report that all Denny's Restaurants are displaying on-premise advertising featuring NATERA Seasoned Chick-Un Tenders and NATERA Chick-Un Nuggets.

To view NATERA On-Premise Advertising at Denny's Restaurants click on image below:

In addition to on-premise advertising featuring NATERA Premium Plant-Based chicken alternatives, Denny's is promoting the entrees through their social media channels which is being augmented by Naturally Splendid social media awareness programs.

Naturally Splendid CEO Mr. J. Craig Goodwin states, "We are proud to see our NATERA plant-based products now available at Denny's and Bar One. I would like to thank Denny's for their tireless work to make this launch happen. This is a significant milestone for the Company, and we look forward to providing our premium plant-based alternatives to Denny's valued customers. We believe we have the best plant-based alternative to chicken and now you can try for yourself at a Denny's or Bar One restaurant near you."

About Naturally Splendid Enterprises Ltd.

Founded in 2010, NSE operates a food manufacturing facility just outside Vancouver, BC in Canada. The Company has established numerous healthy, functional foods under recognized brands such as Natera Sport™, Natera Hemp Foods, CHII, Elevate Me™ and Woods Wild Bar™, and most recently Natera Plant Based Foods, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment. The Company has a myriad of new products and line extensions under development that are approaching launch. NSE, through its joint venture Plasm Pharmaceutical, has been approved for conducting a phase 2 clinical trial approved by Health Canada for treatment of COVID-19. NSE has also developed proprietary technologies for the extraction of high demand, healthy omega 3 and 6 oils from hemp. NSE contract manufacturers for healthy, functional food products and ingredients focusing on plant-based ingredients. The Company provides contract manufacturing services for many healthy food companies, private labeling a wide variety of nutritional food products destined for global healthy food markets.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-465-0548 ext.105

About Denny's Restaurants Canada

Vancouver-based Dencan Restaurants Inc. currently owns and operates 59 Denny's Restaurants across Canada and is owned by Northland Properties Corporation. Part of the highly-regarded worldwide Denny's organization, Dencan Restaurants Inc. has a well-deserved reputation, quality, and guest satisfaction. From fluffy pancakes to crispy bacon and juicy burgers to something from the Fit Fare® Menu, guests will always find delicious value and variety.

For Denny's Restaurants Canada inquiries, contact Pam Jacques at 250 864 6700 | pjacques@northland.ca

On Behalf of the Board of Directors

Mr. J. Craig Goodwin
CEO, Director

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Naturally Splendid Enterprises Ltd.



View source version on accesswire.com:
https://www.accesswire.com/670307/NATERA-Plant-Based-Meat-Alternative-Entrees-Now-Available-in-Dennys-Restaurants-Across-Canada

News Provided by ACCESSWIRE via QuoteMedia

The Conversation (0)
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the pricing of its previously announced public offering (the "Offering") of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share for gross proceeds of US$13.5 million before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering.

The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Row of test tubes and pipette with chemical droplet chemical coming from it.

5 Top NASDAQ Biotech Stocks of 2024

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has traded at three-year highs in 2024 in response to looming interest rate cuts, breakthrough innovations and increased deals in the space.

After dropping to a low of 3,637.05 in October 2023, the index climbed to start 2024 at 4,457.02. It did hit a bump in the road early in Q2 when it plunged to 4,056.3 in April, but it quickly recovered and has since tracked even higher, reaching a high of 4,954.813 on September 19.

While the current economic environment means the biotech sector may have a complex road ahead, robust growth could be in store in the future.

According to a recent report from Precedence Research, the global biotech market is expected to grow at a compound annual growth rate of 11.5 percent from now to 2034, reaching a valuation of US$4.61 trillion.

Keep reading...Show less
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has filed a preliminary prospectus supplement (the "Supplement") to its short form base shelf prospectus dated July 12, 2024 (the "Base Prospectus") in connection with a proposed public offering (the "Offering") of Class A common shares (the "Common Shares"). The Supplement was also filed with the U.S. Securities Exchange and Commission (the "SEC"), as part of a registration statement on Form-10, as amended, which was declared effective by the SEC on July 16, 2024, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Elixinol Wellness Limited

Strategic Acquisition and Capital Raising - Investor Presentation | 3 October 2024

Elixinol Wellness Ltd. (”EXL”) has entered into a binding agreement to acquire 100% of the business assets from the entities ("Acquisition") that together form The Healthy Chef business ("Healthy Chef").

Keep reading...Show less
Radiopharm Theranostics

Significant Progress with B7-H3 Targeting Radio-Antibody (BetaBart)

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce regulatory and manufacturing progress for its B7-H3 targeting radio-antibody, BetaBart.

Keep reading...Show less
Hydralyte

Completion of Divesture of Non-US Assets

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte US” or “the Company”) refers to its announcement released pre-open on 2 October 2024 regarding entry into an Intellectual Property Sales Agreement (the ‘Agreement’) and related documents with Prestige Consumer Healthcare Inc. and associated subsidiaries.

Keep reading...Show less

Latest Press Releases

Related News

×